

From: PRINCIPLE Study
Sent: 18 May 2022 12:04
To: Jared Robinson
Subject: PRINCIPLE SUSAR Update 18.05.2022

PLEASE NOTE THAT THIS EMAIL IS BEING SENT TO ALL PRINCIPAL INVESTIGATORS AT OPEN PRINCIPLE TRIAL SITES.

Dear Colleague,

We would like to update you on the **PRINCIPLE** trial and provide some important details regarding a SUSAR. As part of our safety reporting requirements, we are informing you of a “Suspected Unexpected Serious Adverse Reaction” (SUSAR). This is the third SUSAR reported in the trial.

As you are aware, any Serious Adverse Event (SAE) thought to be related to Favipiravir, by either the Principal Investigator (PI) or the Chief Investigator/Safety Delegate, is classified in the protocol as a SUSAR in accordance with the Investigator’s Brochure. We are sharing the details with all site PIs in the interests of transparency. Details of the SUSAR are listed below, which was reported to the Sponsor, REC and MHRA on 12-May-2022:

What happened?

The participant was randomised to Favipiravir on 09May2022. Participant took IMP on 10May2022 and started developing itching in the genital area. No angioedema. No shortness of breath. High blood pressure. Participant was taken to hospital via ambulance and developed a rash. Heart rate 110 bpm. Pt was given intravenous antihistamines and now recovering, this was their first episode of an acute allergic reaction. No known allergic conditions.

What was the response?

All study procedures were followed as appropriate. The clinician assessing the SAE considered that this was *possibly related* to taking Favipiravir and hence categorised it as a SUSAR. The participant was withdrawn from trial treatment and will be followed up as normal for the 28 day follow up period.

We do not intend to change any trial procedures as a result. **There are no further updates expected regarding this SUSAR.**

Please do remain vigilant for anything that constitutes a SAE throughout your patients’ time on the trial and inform the trial team within 24 hours of becoming aware.

Please do get in touch with the trial team on principle@phc.ox.ac.uk if you have any concerns, and please pass this information on to anyone else working on the PRINCIPLE trial at your practice.

Please ensure you file this email in section on 13.4 of your PRINCIPLE **electronic Investigator Site File**.

To date, the PRINCIPLE trial has recruited **10,766** participants. This is an amazing achievement, and we thank you all for your continuous hard work and support with this important trial. Recruitment remains open to Ivermectin + Usual Care, Favipiravir + Usual Care, and Usual Care alone.

Please do not hesitate to get in touch if you have any queries.

Your sincerely,
The PRINCIPLE Trial Team